[The cardiovascular outcome is critical]

MMW Fortschr Med. 2016 Feb 18;158(3):68. doi: 10.1007/s15006-016-7830-z.
[Article in German]
No abstract available

MeSH terms

  • Benzhydryl Compounds / adverse effects
  • Benzhydryl Compounds / therapeutic use*
  • Biosimilar Pharmaceuticals / adverse effects
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Complications / prevention & control*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucosides / adverse effects
  • Glucosides / therapeutic use*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Glargine / adverse effects
  • Insulin Glargine / therapeutic use*

Substances

  • Benzhydryl Compounds
  • Biosimilar Pharmaceuticals
  • Glucosides
  • Hypoglycemic Agents
  • Insulin Glargine
  • empagliflozin